'Science of Gorgeous' at Lonza
04.04.19
Visit stand L88 for innovative skin, scalp and hair care technologies.
Lonza Home & Personal Care (Stand L88) is pushing the boundaries of science to help brand leaders and product innovators around the world to create cleaner, healthier and more effective products to meet the demands of today’s consumers. Through the company's "Science of Gorgeous" Service, Lonza helps visionary personal care formulators and manufacturers offer value-driven consumers an extensive portfolio of innovative skin, scalp and hair care technologies. Lonza is a leading supplier of non-traditional and traditional functional solutions, including next-gen preservation, chassis ingredients, aesthetic modifiers and bioactives. With strong capabilities in large and small molecules, and biotechnology, Lonza unleashes the power of cosmetic and natural product science to help brands create innovative products.
At the start of In-Cosmetics, Lonza AG announced that it and Chr. Hansen Holding A/S, a leading global bioscience company, signed an agreement to establish a 50/50 joint venture to pioneer the live biotherapeutic products (LBPs) industry and position themselves as the leading contract development and manufacturing partner (CDMO) for biotech and pharma customers. The JV will operate from headquarters in Basel and have production facilities in Denmark and Switzerland.
The joint venture, according to Lonza, brings together best-in-class, complementary capabilities and will be the first CDMO globally to provide a full supply chain that offers manufacturing of bacteria strains for therapeutic use. While Chr. Hansen contributes its extensive know-how in developing, upscaling and manufacturing bacteria strains, Lonza brings strong capabilities in pharma contract manufacturing and outstanding formulation and drug delivery technologies, including the unique enTRinsic capsules.
Furthermore, the joint venture will possess leading competences in handling, characterizing, formulating, manufacturing and encapsulating strict anaerobe bacteria. These competences under one roof, with seamless exchanges between drug substance and drug product activities, will decrease development timelines and increase chance of “right-first-time.”
"We need to think differently about how we develop solutions for manufacturing in the microbiome space as we see the potential of this therapeutic area develop,” said Marc Funk, CEO, Lonza Group. “By teaming up with Chr. Hansen, one of the world’s largest producers of bacteria, we are combining expertise that perfectly fits the very specific needs of aspirational companies in the microbiome space. Our customers will be able to draw on the unrivalled skillset of two world experts that master the exacting processes required for production of strict anaerobic microbes through to formulation and dosage forms. We understand the complexities of bringing pharmaceuticals to market, including the evolving regulatory environment and will offer unique development and pharma-grade manufacturing that addresses an unmet need in the industry, enabling customers to deliver therapies for patients.”
For more information on Lonza Home & Personal Care:
Tel: +1 862-262-1700, Fax: +1 618-258-6808
412 Mt Kemble Ave, Suite 200S, Morristown, NJ 07960 US
At the start of In-Cosmetics, Lonza AG announced that it and Chr. Hansen Holding A/S, a leading global bioscience company, signed an agreement to establish a 50/50 joint venture to pioneer the live biotherapeutic products (LBPs) industry and position themselves as the leading contract development and manufacturing partner (CDMO) for biotech and pharma customers. The JV will operate from headquarters in Basel and have production facilities in Denmark and Switzerland.
The joint venture, according to Lonza, brings together best-in-class, complementary capabilities and will be the first CDMO globally to provide a full supply chain that offers manufacturing of bacteria strains for therapeutic use. While Chr. Hansen contributes its extensive know-how in developing, upscaling and manufacturing bacteria strains, Lonza brings strong capabilities in pharma contract manufacturing and outstanding formulation and drug delivery technologies, including the unique enTRinsic capsules.
Furthermore, the joint venture will possess leading competences in handling, characterizing, formulating, manufacturing and encapsulating strict anaerobe bacteria. These competences under one roof, with seamless exchanges between drug substance and drug product activities, will decrease development timelines and increase chance of “right-first-time.”
"We need to think differently about how we develop solutions for manufacturing in the microbiome space as we see the potential of this therapeutic area develop,” said Marc Funk, CEO, Lonza Group. “By teaming up with Chr. Hansen, one of the world’s largest producers of bacteria, we are combining expertise that perfectly fits the very specific needs of aspirational companies in the microbiome space. Our customers will be able to draw on the unrivalled skillset of two world experts that master the exacting processes required for production of strict anaerobic microbes through to formulation and dosage forms. We understand the complexities of bringing pharmaceuticals to market, including the evolving regulatory environment and will offer unique development and pharma-grade manufacturing that addresses an unmet need in the industry, enabling customers to deliver therapies for patients.”
For more information on Lonza Home & Personal Care:
Tel: +1 862-262-1700, Fax: +1 618-258-6808
412 Mt Kemble Ave, Suite 200S, Morristown, NJ 07960 US
